87.05 0.00 (0.00%)
After hours: 4:11PM EDT
|Bid||84.45 x 800|
|Ask||89.83 x 1300|
|Day's Range||85.94 - 89.11|
|52 Week Range||85.94 - 130.00|
|Beta (3Y Monthly)||0.86|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Arena Pharmaceuticals (ARNA) reports loss in the first quarter of 2019 on an adjusted basis. Revenues of $801.1 million include upfront payment of $800 million from United Therapeutics.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Anyone researching United Therapeutics Corporation (NASDAQ:UTHR) might want to consider the historica...
United Therapeutics Corp NASDAQ/NGS:UTHRView full report here! Summary * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for UTHR with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $5.64 billion over the last one-month into ETFs that hold UTHR are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
United Therapeutics Corp. suffered its first major blow from generic competition as sales of its pulmonary arterial hypertension drug, Adcirca, plummeted in the first quarter of this, driving the company to eye new business lines to make up for the hit. The Silver Spring biotech's first-quarter total revenue was dragged down about 7%, to $362.6 million from $389.2 million in the same period last year. United Therapeutics (NASDAQ: UTHR) sold fewer bottles of the Adcirca tablets after its patent expired and a generic version of the drug hit the market in August, according to Securities and Exchange Commission filings.
United Therapeutics (UTHR) beats estimates on both fronts in the first quarter. However, earnings and revenues decline year over year.
United Therapeutics (UTHR) delivered earnings and revenue surprises of 35.61% and 9.72%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Silver Spring, Maryland-based company said it had a loss of $11.32. Earnings, adjusted for non-recurring costs and stock option expense, were $3.58 per share. The results exceeded ...
United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hedge funds and other investment firms run by legendary investors like Israel Englander, Jeffrey Talpins and Ray Dalio are entrusted to manage billions of dollars of accredited investors' money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to […]
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as United Therapeutics Corporation (NASDAQ:UTHR), with a market capitalization of US$4.8b, rarely draw their attention from the investing commun...
United Therapeutics (UTHR) discontinues the development of esuberaprost, as the phase III study fails to meet primary endpoint.
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) reported Thursday mixed results from a phase 3 clinical trial for its attention deficit hyperactivity disorder treatment — and investors were not pleased. The Rockville company, which focuses on products for central nervous system diseases, failed to demonstrate that a 600-milligram dose of its drug candidate, called viloxazine hydrochloride, could effectively reduce ADHD symptoms in adolescents. The stock dipped Thursday as much as 4 percent to $32.90 per share before crawling up to $34.18, a 0.58 percent drop from Wednesday's closing price, by 3 p.m. But Supernus President and CEO Jack Khattar said this latest outcome won't stop the company from advancing the product to market, according to remarks he made on a conference call about the results.
How Major Rare Disease Pharma Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 2.45% for United Therapeutics (UTHR) based on the stock’s closing
MannKind or Akebia: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)Financial performance In the fourth quarter, MannKind Corporation (MNKD) reported revenue of $16.03 million, a YoY (year-over-year) rise of 253.91%. According
United Therapeutics Corporation (NASDAQ:UTHR) shareholders might be concerned after seeing the share price drop 13% in the last week. But the silver lining is the stock is up over fiveRead More...